MRKMerck Sharp & Dohme LLCSigning up patients
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Lung Neoplasm Malignant
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 1/2
- Patients
- 140 (planned)
- Started
- Apr 30, 2026
- Main results expected
- Aug 17, 2029
- Fully finished
- Apr 13, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants Who Experience a Dose Limiting Toxicity (DLT)
Measured over: Up to 42 days
Number of Participants Who Experience an Adverse Event (AE)
Measured over: Up to approximately 63 months
Number of Participants Who Discontinue Study Treatment Due to an AE
Measured over: Up to approximately 62 months
Objective Response Rate (ORR)
Measured over: Up to approximately 63 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07286149 · record last updated 2026-10-01 · checked 2026-11-09 15:47 UTC